Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hmmm ...
The right PR ...
... will blow the 200 DMA out of the water.
EOM
Oh ya ...
... I think there's more in the oven here than we might think. Here's copy of an email I received from James Ketner, back on 4/21/2011:
Hello XXXXXX,
I have been buying back the float over the past year. I sold my CLS and bought stock when it was down at 5 cents. We got into this medical stuff when we were part of a chain to a supplier of Stryker. We were making 40 units a month, and that was for one client. If, IF, we can make 40 units a month, with our current share structure, and with a P/E of 20, the stock is worth $3.80 per share.
I always envisioned us being on the NASDAQ some day, and that is why I have always been so stingy with the stock. A/S 20m, O/S 12m, Float 7m (of which I am holding 2m, and my friends are holding most of the rest, and we are not going anywhere under 3 dollars)
Hope this answers some of your questions. Again, thanks for your input on the website. I really appreciate it !!
jw
That email is a little over 9 months old, and the float is a little higher, etc., but ... I think we have a winner here.
EOM
Okay ...
... here's the scoop (or at least part of it).
I just got off the phone with Thomas Cleary, he returned my call. I told him about the T/A clamming up, etc., and he had no real comment to that, but he told me that A/S is still 20M and the float is somewhere around 13M. I asked about future dilution and he said that wasn't in the immediate picture (take that for what you will).
The 'press release' on the website was NOT mean't to be published, just posted on the site to help answer some questions to-date. He said the former CEO (I assume he mean't James Ketner) actually "left" on 12/12/2011 (for whatever that info is worth). He mentioned they're expecting an RFP in about 2 weeks regarding another client. He mentioned they're looking at another possibility of 'expanding' into a joint venture. He said these potential clients are calling KLYG also, not so much the other way around. Lastly, he said either end of this week or next week, they're shooting for a website update on the financials. Meanwhile, they're still hunting for an IR person, and he has an interview with one tomorrow.
Sorry I can't be more specific on some issues. He did say he has no problem with people calling.
So ... there ya have it.
EOM
Don't worry ...
... about not being a whiz at the financials, I'm not either ... I'm better at operating in stealth mode, and wiping out the enemy.
I did call the T/A in Oregon ... and he told me he couldn't give me the technical info about the stock, and that I needed to get it from the company. So ... I'm hoping to continue communication with Chris and eventually Mr. Thomas Cleary, who is (per Chris) handling investor relations until they hire somebody. They're hard as hell to get over the phone, earlier in the morning seems to be the best time (or has been in the past). Regardless, I've left another phone message, and am waiting on another email response from Chris.
EOM
Another update ...
... from a Chris email:
" ... What I can tell you from firsthand experience is that the majority of that list we have had purchase from us. There is a small part of it that we have estimates to and are promised orders. We are in talks with other major trauma centers that we have been approved at but have no activity from, so we decided to leave them off the list so we were not misleading.
We do plan, in the near future to address all financial concerns and provide projects based on feedback and research. These numbers have taken a little longer to put together than expected because we want to ensure the accuracy of all statements released. The public will begin to see the results of the work our new management team has done over the last 45 days. In my opinion it should eliminate some of the fears that are out there now...."
He also told me the "list" has been, or will be edited, and that the incorrect one apparently got posted. I have yet to hear back regarding the issue of why this press release did not hit the internet. I was told Thomas Cleary is heading up investor relations until a full-time can be hired. I hope to communicate with Thomas soon, and will report what I find out.
EOM
Ooops ...
... I stand corrected. There are repeats in the list at the bottom (bad proof-reading by someone). Also, there are several hospitals up the list that are part of a hospital "system", such as the Methodist Hospital System: http://www.methodisthealth.com/ourHospitals.cfm?id=36837
Slap my hand (not too hard!)
EOM
Myself ...
... I don't think they're dropping shares, or issuing them - at least not a significant amount. I don't know that for sure, but I doubt it. An email to me from Mr. Ketner back in April of 2011, said A/S 20M, O/S 12M, and Float 7M (2M his alone, and most of the rest with people he knew).
Regarding the hospital list, I wouldn't call them 'repeats'. They have the same pre-name, yes, and very well could be associated, but they are definitely separate facilities ... especially the lines/numbers you listed (I used to live in Houston, TX).
Lastly, I communicated via email with Mr. Chris Breault, VP of Operations. His reply included this:
" ...Thank you for your email. I would like to apologize for the financials. We did switch accounts and were set back a few times during this process. We will be releasing a statement on the financials in the next week...."
EOM
Did anyone notice ...
... there's a "news" article on the website, dated yesterday?
http://www.kelyniam.com/archives/260
EOM
Contrary to ...
... many of the posts on this board, Amir does exist, and I know that because I know how to use a telephone. Amir also apparently closed on the PURCHASE of his house on Aug. 2, 2011, for $170K. A search on 'Realtor.com' will confirm that: http://www.realtor.com/realestateandhomes-detail/170-Hillsborough-Ln_Lenoir-City_TN_37772_M70288-69891
It cracks me up when I read all these posts (and you all know who you are). But ... I also have to remember what site this is, and how dishonest people in this world can be. It's reality, unfortunately ... but it's a shame.
EOM
Interesting note ...
... in the 10-K/A filing, which was filed with the SEC - and accepted - on 10/25/2011.
It amazes me ...
... how many people on this site don't know how to use a telephone! LMAO!
EOM
If you wait ...
... for the phone to ring, after several rings a message comes on, from Erwin Vahlsing, Jr., the CFO, asking you to leave a message and number and he'll return your call.
EOM
Didn't have a chance ...
... to speak with him at length. I heard another phone ringing in the background, and he said he had to get another call. I may try again in a bit.
EOM
That's interesting ...
I just called, held the line as the recording requested, and a rep picked up the call. Started talking to him, he mentioned "debt conversions taking place ... hold your stock ...", and then said he had another call and had to go.
The Kelyniam scoop ...
Here's my email to KLYG yesterday:
From: XXXXXX
To: tanthony@kelyniam.com
Subject: KLYG Stock
Hello Mr. Anthony,
I am a stockholder in KLYG, and I called your company this morning to ask a couple of questions. A very nice lady answered the phone (I assume a secretary) and I spoke with her.
I was calling for two reasons. First, yesterday I called your website-listed Investor Relations contact, Mr. Christian Scarborough, and I spoke with him. He indicated to me that he is no longer the Investor Relations contact for your company, that he has been receiving several phone calls regarding Keylniam Global, and he wished that you folks would edit/correct that information on your website.
Secondly, I had communicated with Mr. James Ketner several months ago, via phone and email, and I was concerned that his name is no longer showing up on the website, so I was wondering whether Mr. Ketner was still with the company. I didn't ask in what capacity, but the lady that I spoke with did tell me that Mr. Ketner is still with the company.
Those two concerns was the reason for my calling, and I was also prompted by the latest press release. Being a stockholder, of course I am hoping that KLYG prospers. Will a new/different investor relations contact be obtained? From your point of view, is the future bright? I realize you are limited on what information you can tell me, but I am hoping for the best for all of us!
Kind regards,
XXXXXX
The reply I received today:
To: XXXXXX
From: Tennyson Anthony
Subject: Re: KLYG Stock
Dear Mr. XXXXXX,
Thank you for your inquiries into Kelyniam Global, Inc..
First, let me start by saying that Mr. Ketner is no longer with the Company. He has chosen to move on to other opportunities but stays in touch. Second, let me apologize for the confusion on our web site about Mr. Scarborough. It is true that he is no longer acting as our investor relations contact and at this time we have not found the right person to fill that position but will be shortly, so please keep watching our site for when that happens.
As the new President and CEO, I can tell you that I am extremely optimistic about the future of Kelyniam. We have started selling/shipping our product and the feedback from the doctor's has been great. We are presently working to open the Canadian market and anticipate that to happen in 2012. We are also working to be able to sell in the middle east and specifically Saudi Arabia and Kuwait and are optimistically shooting to be able to start selling over there late 2012 as well.
So as you can see we have our work cut out for us but are working extremely hard to make Kelyniam the Global leader in cranial implants.
Thank you for your support.
Tennyson S. Anthony, Esq.
President/Chief Executive Officer
Kelyniam Global, Inc.
97 River Road, Canton, CT 06019
(800) 280-8192 Ext. 710
EOM
See ...
... Post# 28290.
EOM
Uh-huh ...
... and mine says:
IGSM GROUP INC COM REVERSE SPLIT@ .004 NEW CUSIP XXXXXXXX
EOM
All I can say is ... WOW!!!
Mr. Charles ...
From the article ...
http://www.designnews.com/article/518204-Custom_Implants_Delivered_in_One_Day.php
Nice volume ...
... and movement today! With that sob bin Laden now toast, we can concentrate on ANWM.
Good luck to all!
EOM
KAAA-BOOOOOM!!!!!
EOM
FDA APPROVAL ... !!!
... at long last!
Check out the news alert, post #1628 and the new Kelyniam Global, Inc. website:
http://www.kelyniam.com/
EOM
Holy Implants! ...
... KLYG just got FDA approval!!!
Kelyniam Receives FDA 510(k) Clearance to Market Cranial Implants
Wednesday April 20, 2011 - 16:00 PM EDT
Marketwire News Releases - Released By Kelyniam Global, Inc.
NEW BRITAIN, CT -- (Marketwire) -- 04/20/11 -- Kelyniam Global, Inc. (PINKSHEETS: KLYG), an emerging medical device manufacturer, today announced that it has received clearance from the U.S. Food and Drug Administration to begin marketing its Patient Specific Custom Cranial Implants.
The Kelyniam Custom Skull Implants (CSI) are designed and manufactured for each individual patient to correct or replace bony voids in the cranial skeleton caused by trauma or birth defects. Streamlined CAD/CAM design and manufacturing techniques will enable Kelyniam to deliver patient specific implants to surgeons in as little as 24 hours from the receipt of an order, unlike similar products on the market that require 4-5 weeks for delivery. The ability to provide custom implants quickly and accurately will reduce the time between trauma and implantation and provide surgeons additional treatment options.
Kelyniam began the development of these new medical devices in the second quarter of 2009. In less than 2 years, the company has perfected a process to quickly and accurately deliver high tolerance, patient specific custom skull implants using PEEK-OPTIMA®. The regulatory expertise gained during the submission process will be applied to future Kelyniam products.
"Receiving the 510K clearance has validated our strategy of applying advanced engineering techniques to specific segments of the medical device market. We are pleased to have reached this milestone," said James Ketner, Kelyniam's President & CEO. "The approval of Kelyniam's Custom Skull Implants allows us to provide our customers unsurpassed service and the most advanced Patient Specific Implants available. Entering the multi-billion dollar trauma fixation market with a high quality custom implant will position Kelyniam as a service oriented leader in the custom device segment."
Kelyniam will now focus on the sales, manufacturing, and customer support of Kelyniam's Custom Skull Implants. The company plans to develop and in-license additional medical devices for surgical markets. The products will be marketed through independent sales representatives with strong relationships in their respective territories.
About Kelyniam Global, Incorporated:
Kelyniam Global, Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
Forward-Looking Statements
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believes," "estimate," "expect," "should," "intend," "projects," "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.
Embedded Video Available: http://www2.marketwire.com/mw/frame_mw?attachid=1584701
Contact:
Kelyniam Global, Inc.
www.kelyniam.com
1-800-280-8192
Email Contact
EOM
Whoa Nelly! ... something's UP!!!
EOM
Who IS "Sidney Richlin"? ...
Here's an interesting link, found through a "Sidney Richlin" 'Google' image search:
http://www.sidneyrichlin.com/
Check out the "Vital to the Imagination" upper-left video ... also the "Earloomz.com" link/site for another "Sidney Richlin" video (notice the 'SuperRadToys.com' link under 'Recommended Websites').
EOM
It's called "dilution pollution".
EOM
For what it's worth ...
... I've communicated enough with the mod of this board, via phone and otherwise, to know that he's an honest and trustworthy individual.
EOM
Headfake ... or something coming?
EOM
Happy Veteran's Day ...
... to all vet's out there, near and far.
EOM
The word is getting out ...
http://www.msnbc.msn.com/id/39898804/ns/business-going_green/
EOM
Goin' north ...
... and EVRN likes Friday market-close PR's.
EOM
Generex Common Stock to be Quoted on the OTCQB Under the Symbol 'GNBT' Beginning Thursday, October 21, 2010
--Common Stock will no longer be traded on the NASDAQ Capital Market beginning on that date --Generex Will Continue to Pursue its Product Development & Commercialization Initiatives Unabated
WORCESTER, Mass., Oct 19, 2010 /PRNewswire via COMTEX News Network/ -- Generex Biotechnology Corporation (www.generex.com) announced today that on October 19, 2010 the NASDAQ Listing Qualifications Panel notified the Company that the Panel has determined to delist the Company's common stock from the NASDAQ Capital Market and will suspend trading of the stock effective at the open of trading on Thursday, October 21, 2010 as a consequence of the Company's non-compliance with NASDAQ's minimum $1.00 per share closing bid price requirement.
The Company has been advised by Pink OTC Markets Inc., which operates an electronic quotation service for securities traded over-the-counter (OTC), that the Company's common stock is immediately eligible for quotation on the OTCQB effective with the opening of the markets on October 21, 2010. The OTCQB is a market tier for OTC traded companies that are registered and reporting with the Securities and Exchange Commission. The Company has also been advised that its common stock will continue to trade under the symbol "GNBT". Investors will be able to view real time stock quotes for GNBT at http://www.otcmarkets.com.
In September, 2010, there were 3,871 securities quoted on the OTCQB and the aggregate dollar value traded was just under $4 billion.
Generex management and its Board of Directors remain fully committed to the aggressive pursuit of the Company's product development and commercialization initiatives. "The move to the OTCQB is not reflective of the value and tremendous potential of our pipeline," said Mark Fletcher, the Generex Interim President & Chief Executive Officer. "Our efforts to move our pipeline products forward to commercialization will continue unabated."
At the reconvened Special Meeting of the Company's stockholders held on October 18, 2010, the reverse stock split proposal put forward by the Company's Board of Directors as a means of maintaining the Company's NASDAQ listing did not achieve the necessary vote in time for the meeting.
Of the 269,360,643 shares outstanding as of the August 12 record date, 191,872,323 shares (71.24%) were voted. The 127,819,048 shares voted in favor of the proposal represented 66.61% of votes cast and 47.45% of the outstanding shares. Approval of the proposal required a majority of the outstanding shares to vote in favor; accordingly, the vote fell 2.56% short.
During the week following the Company's October 11th announcement of its pending acquisition of a 51% equity interest in Global Medical Direct, LLC, interest in the reverse stock split proposal increased dramatically. During that period, the number of shares voted in favor of the proposal increased by 42,312,013 (an increase of nearly 50%) and the number of shares voted against the proposal decreased by 29,497,077 (a decrease of almost 32%) and the number of shares voted overall increased by 11,749,664 (a 13% increase).
In light of the increased stockholder support for the reverse stock split proposal as evidenced by the voting pattern over the past week, the Company will appeal the Panel's delisting determination to the NASDAQ Listing and Hearing Review Council. The Listing Council is a standing independent advisory committee appointed by NASDAQ's Board of Directors that, among other things, hears appeals of Panel decisions to delist. The suspension of the Company's common stock from trading on NASDAQ will remain in place throughout the appeal process, although the stock will be quoted on the OTCQB during that time.
About Pink OTC Markets Inc.
Pink OTC Markets Inc. is a financial information and technology services company that operates an inter-dealer electronic quotation and trading system in the Over-The-Counter (or OTC) securities market. It is not registered with the Securities and Exchange Commission as a stock exchange or broker-dealer firm. Investors should contact a broker-dealer firm to trade in a security quoted on the OTCQB or the other OTC tiers operated by Pink OTC Markets Inc. More information is available at http://www.otcmarkets.com.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's buccal insulin spray product, Generex Oral-lyn(TM), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation
EOM
Goin' north?!
EOM
Guess all those ...
... $.007+ buys were a little 'early' then?!
EOM